NCT05433116 - Pembrolizumab and Lenvatinib After Definitive Chemoradiation of Locally Advanced HNSCC | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 25, 2023

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2026

Conditions

Head and Neck Squamous Cell Carcinoma

Interventions

DRUG

Pembrolizumab

i.v., 200mg absolute, q3w, starting within 14 days after completion of radiochemotherapy

DRUG

Lenvatinib

20mg once daily orally, start concomitant to cycle 2 of pembrolizumab

Trial Locations (10)

35392

RECRUITING

University Hospital Giessen; Ear, nose and throat clinic, Giessen

40225

RECRUITING

University Hospital Düsseldorf, Radiation Oncology, Düsseldorf

60590

RECRUITING

University Hospital Frankfurt/M, Center for Radiology, Frankfurt am Main

66421

RECRUITING

Saarland University Medical Center and Saarland University Faculty of Medicine, Clinic for Radiotherapy and Radiooncology, Homburg

86156

RECRUITING

University Hospital Augsburg, Radiation Oncology, Augsburg

89070

RECRUITING

University Hospital Ulm, Otolaryngology & Head and Neck Surgery, Ulm

91054

RECRUITING

University Hospital Erlangen, Radiation Oncology, Erlangen

93053

RECRUITING

University Hospital Regensburg, Clinic and Polyclinic for Radiotherapy, Regensburg

09116

RECRUITING

Hospital Chemnitz, Radiation Oncology, Chemnitz

01307

RECRUITING

Gemeinschaftspraxis Hämatologie-Onkologie, Dresden

All Listed Sponsors

lead

Universität des Saarlandes

OTHER